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mergency Department
evin Wei, MD
ortland, Oregon
he diagnosis and risk stratification of patients presenting with suspected cardiac chest pain to the
mergency department (ED) is difficult, inefficient, and costly. Echocardiography can be used to directly
etectmyocardial ischemia through the identification of a newwall thickening (WT) abnormality. Contrast
chocardiography provides further incremental benefit both for assessment of WT, as well as from the
valuation of myocardial perfusion. This review will discuss how echocardiography can be used to diag-
ose, risk stratify, and potentially reduce costs in patientswith suspected acute coronary syndromes in the
D. (J Am Coll Cardiol Img 2010;3:197–203) © 2010 by the American College of Cardiology Foundationi
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iverhe diagnosis of an acute coronary syn-
drome (ACS) has relied on the history, the
presenting electrocardiogram (ECG) and
serial cardiac serum biomarkers for decades.
his practice has not changed even though a
atient’s description of their symptoms can be
ighly variable, and up to a quarter of patients
ith acute myocardial infarction (AMI) have no
hest pain (CP) or a main complaint other than
P (such as dyspnea, fatigue, or abdominal dis-
omfort) (1). Women are much more likely to
resent with atypical symptoms such as jaw rather
han chest pain, or with nausea or vomiting (2).
f the estimated 5.6 million annual emergency
epartment (ED) visits for CP, 10% present
ith ST-segment elevation (3). In a study of
,814 patients presenting with CP to the ED,
3% of the presenting ECGs were called normal
r nondiagnostic (4). The sensitivity of serum
ardiac markers for an AMI is very poor until
any hours after the onset of symptoms (5), and
atients with unstable angina (UA) have no
levations of serum cardiac markers by definition
3). Single determinations of creatine kinase at
he time of patient presentation have a sensitivity
f only 36% for detecting AMI. The sensitivity
rom the Cardiovascular Division, Oregon Health and Science Un
s Guest Editor for this paper.anuscript received May 27, 2009; revised manuscript received July 2ncreases to 69% at 4 h, and to 95% to 99% by
5 h (1). Likewise, cardiac troponins and myo-
lobin also have limited sensitivity early after the
nset of ischemia.
Cardiac ischemia is the most common “life-
hreatening” cause of CP in patients presenting to
n ED. However, only 10% to 30% of patients
ho present with CP are eventually diagnosed
ith an ACS (6–8). In the ACI-TIPI (Acute
ardiac Ischemia Time-Insensitive Predictive
nstrument) study (9) that included 10,689
atients at least 30 years of age, presenting with
hest, left arm, jaw, or epigastric pain or dis-
omfort, dyspnea, or other symptoms sugges-
ive of acute ischemia, an ACS was diagnosed
n only 17% of patients (AMI in 8% and UA in
%), whereas nonischemic cardiac conditions
ere diagnosed in 21% and noncardiac prob-
ems in 55%.
Although most patients end up having minor
auses of CP, prolonged observation and exten-
ive workups are currently required prior to dis-
harge. The cost of excluding ACS is 8 to 10
illion dollars annually in the U.S. alone, and
ime consuming for both physicians and patients.
n the other end of the spectrum, up to 11% of
sity, Portland, Oregon. Sanjiv Kaul, MD, served8, 2009, accepted September 17, 2009.
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198atients are inadvertently discharged from the ED
ith a missed AMI (average 2.1%), and UA is
issed in up to 4% (5,10–12). This misdiagnosis
nd inappropriate discharge leads to increased mor-
ality for those patients who have an AMI outside
he hospital (12).
Thus, in patients with CP but without suggestive
vidence of ACS at the time of presentation (such as
he presence of ST-segment elevation, tall “peaked” T
aves, ST-segment depression, or deep T inversions
n the initial ECG, or elevated cardiac serum mark-
rs), a tool that could improve our diagnostic acumen
or ACS, and help exclude cardiac CP in all other
atients would be invaluable. Such a tool would need
o detect either anatomically significant coronary ar-
ery disease, reduced perfusion to myocytes, or the
consequences of abnormal perfusion (e.g.,
abnormal cardiac function). Ideally, such a
tool would also be rapid, noninvasive, highly
accurate, safe, and portable. In recent years, a
variety of cardiac imaging modalities that can
assess left ventricular systolic function, myocar-
dial perfusion, or coronary anatomy have been
evaluated for this purpose, including echocar-
diography, single-photon emission computed
tomography (SPECT), cardiac magnetic res-
onance, and electron beam or multi-detector
computed tomography. Among them, echo-
cardiography is the only technology that can be
performed rapidly at the patient’s bedside,
without having to discontinue monitoring or
move the patient out of an acute care setting,
even when the patient is still symptomatic
and receiving ongoing treatment.
Even if a diagnosis of ACS is made
expediently, risk stratification is still required
to determine whether the patient should be
referred for early invasive evaluation, or
hether conservative management alone is adequate.
igh-risk clinical features such as recurrent angina at
est, elevated cardiac biomarkers, dynamic ST-
egment depression, congestive heart failure, hemody-
amic instability, high-grade ventricular arrhythmias,
r a history of recent revascularization can help to
dentify patients most likely to benefit from early
ardiac catheterization (3). Most patients with an
CS, however, do not present with these features, so
ncillary imaging that can risk stratify patients quickly
ould also be invaluable.
athophysiology of ACS
ue to the autoregulatory capacity of the coronary
ome
t
w
n
lysis
ion
ssionicrocirculation, resting myocardial blood flow dMBF) remains constant over a wide range of coro-
ary driving pressures (13). Consequently, MBF does
ot fall below normal resting levels until a coronary
bstruction exceeds 85% to 90% of the luminal area of
n epicardial coronary artery (14). With such critical
tenoses, supply/demand mismatch can result in an-
ina occurring at rest, which is one of the 3 principal
resentations of UA (3). The coronary lesion most
ommonly associated with the development of an
CS is characterized by erosion or disruption of an
therosclerotic plaque, with resultant nonocclusive
hrombus formation which reduces resting MBF and
eads to an ACS. UA and non–ST-segment elevation
yocardial infarction (NSTEMI) share the same
athophysiology, with NSTEMI being a more serious
anifestation of the process. An NSTEMI is associ-
ted with myocardial injury and detectable quantities
f biomarkers. If there is no biomarker evidence of
ecrosis, the patient is determined to have UA (3).
chocardiography in Suspected ACS
he use of 2D echocardiography to detect ACS is
ased on a close relationship between resting MBF
nd regional wall thickening (WT). Because myocar-
ial contractility is a major determinant of myocardial
xygen consumption, reductions in resting MBF are
ollowed within seconds by the development of hypo-
inesis (Fig. 1) (15). Normal resting MBF (1
l·kg1·min1) is associated with WT of approxi-
ately 30%. With acute reductions in resting MBF,
T abnormalities develop within seconds. Thus, the
ssessment of WT provides a direct measure of the
resence of myocardial ischemia. Even a brief coro-
ary occlusion (5 to 15 min) results in severely reduced
egional systolic function (15). Depending on the
uration and severity of the ischemic insult, and the
dequacy of reperfusion, these functional changes are
vident for hours despite reperfusion, and may take up
o 48 h to normalize (16–18).
The use of echocardiography to evaluate for WT
bnormalities is a class I indication in patients with
uspected myocardial ischemia but nondiagnostic
CG and negative cardiac serum markers (19).
Early studies evaluating echocardiography in pa-
ients presenting to the ED with CP found that WT
ad a high sensitivity for detecting AMI (92% to 93%)
nd cardiac ischemia (88%); however, the specificity
as limited to 53% to 57%, and 78%, respectively
20,21). WT abnormalities can be detected even if
atients present many hours after their index event
22). In patients who suffer an NSTEMI with suben-B B R E V I A T I O N S
N D A C R O N YM S
CS acute coronary syndr
MI acute myocardial
nfarction
P chest pain
CG electrocardiogram
D emergency departmen
BFmyocardial blood flo
CEmyocardial contrast
chocardiography
Pmicrovascular perfusio
TIMImodified Thrombo
nMyocardial Infarction
STEMI non–ST-segment
levation myocardial infarct
PECT single-photon emi
omputed tomography
A unstable anginaocardial or even patchy myocellular necrosis, WT
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199bnormalities are persistent since WT is derived
ainly from the inner 20% to 30% of the myocardium
23). Although wall motion abnormalities are present
n patients with remote myocardial infarction, old
carred segments are often thinned, whereas wall
hickness may be preserved in the setting of an ACS.
ncremental Benefits of Contrast Agents for
chocardiographic Detection of ACS
t is critical to evaluate WT of all segments accurately,
o microbubble contrast agents must be considered to
nhance delineation of left ventricular endocardial
orders (24–26). It has recently been shown in a study
here technically difficult patients received contrast
gents that the percentage of visualized segments
ncreased from 68% to 99%, and the proportion of
egments with an identified WT abnormality in-
reased from 16% to 23%. The detection of these
bnormalities resulted in a direct impact on patient
anagement (27). False negative studies, however,
ave also been reported in up to 1% of patients with a
mall AMI detected only by serum cardiac markers
19,20).
Myocardial contrast echocardiography (MCE) can
lso be used to assess microvascular perfusion (MP).
hus, MCE can directly detect reduced resting MBF
s well as its consequences on WT. Microbubbles
emain entirely intravascular, are hemodynamically
nert, and have a microvascular rheology identical to
hat of red blood cells (28,29). These properties make
icrobubbles excellent tracers for assessing MBF.
Microbubbles reside exclusively within the vascular
pace, so they act as blood pool agents, and their
oncentration in the myocardium reflects the myocardial
lood volume (MBV), 90% of which is in capillaries.
hus, steady-state contrast enhancement provides an
ssessment of capillary blood volume (30). At steady state
uring a continuous intravenous infusion of micro-
ubbles, the number of microbubbles entering or leaving
ny microcirculatory unit is constant, and will depend on
he flow rate. By destroying microbubbles with an ultra-
ound pulse, and then determining the rate of replenish-
ent of microbubbles into tissue, microbubble (or
ed blood cell) velocity can be determined (MBF
elocity) (31). In an ACS, reduced MBF of the
schemic segments will be manifested by both
educed MBF velocity as well as MBV, which will
ppear as slow contrast enhancement and a suben-
ocardial perfusion defect.
Figure 2 shows echocardiographic images from aoman with no prior cardiac history presenting withyspnea to the ED and a nondiagnostic ECG, dem-
nstrating akinesis of the mid to distal septum, ante-
ior wall, and apex in the apical 4-chamber view (Fig.
A, end-diastole; Fig. 2B, end-systole, with akinetic
Figure 1. Relation Between MBF and WT
The echocardiographic detection of myocardial ischemia is based o
pathophysiologic relation illustrated in this ﬁgure. Normal resting m
blood ﬂow (MBF) of 1 ml/min/g of tissue is associated with wall thi
(WT) of 20% in this experimental animal model. Reductions in restin
with a screw occluder are followed within seconds by the developm
hypokinesis. Modiﬁed, with permission, from Leong-Poi et al. (15).
Figure 2. Echocardiographic Images of a Patient With CP
(A) End-diastolic apical 4-chamber view of the left ventricle. (B) End-
systolic apical 4-chamber view of the left ventricle. Akinetic septum
and apex delineated by arrowheads. (C) Apical 3-chamber view dem-
onstrating a perfusion defect in the anterior septum (arrowheads).
(D) Apical 3-chamber view demonstrating a persistent subendocardial
defect, with replenishment of microbubbles into the mid- and subepi-n the
yocardial
ckening
g MBF
ent ofcardium of the septum (arrowheads). CP  chest pain.
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200erritory delineated by arrowheads). Perfusion imaging
sing harmonic power Doppler was performed to
valuate resting MBF. This demonstrated a slow rate
f replenishment of microbubbles into the anterior
eptum in the apical 3-chamber view (denoting either
ery slow antegrade flow in the left anterior descend-
ng coronary artery due to a critical stenosis, or a
ompletely occluded left anterior descending coronary
rtery with slow collateral flow) (Fig. 2C). At a long
ulsing interval of 8 cardiac cycles, however, nearly
omplete contrast enhancement of the entire akinetic
erritory except for a subendocardial perfusion defect
Fig. 2D), denoting extensive microvascular integrity
nd viability despite prolonged ischemia.
iagnostic and Prognostic Utility of MCE in
uspected Cardiac CP
he accuracy, clinical utility, diagnostic, and prognos-
ic value of MCE have been evaluated in the ED
etting (32–34). In a multicenter study comparing
CE with SPECT, it was found that the 2 imaging
odalities were equal in their ability to diagnose
MI. In terms of predicting future cardiac events,
CE provided a 17% increase in incremental infor-
ation for predicting future events which was com-
arable with the 23% increase in information with
PECT (32). More recently, WT assessed with
CE was shown in a large single-center study to
ncrease significantly the diagnostic information over
emographic variables, clinical risk factors, and ECG
ata (Bonferroni-corrected p 0.0001) for predicting
ardiac-related death, AMI, UA, congestive heart
ailure, and revascularization within 48 h of ED
resentation (33). When MP was added, significant
dditional diagnostic information was obtained
Bonferroni-corrected p  0.0002) (33).
As previously discussed, apart from the identifica-
ion of ischemia, accurate risk stratification of CP
atients is also important. Those who are intermediate
r high risk for an adverse outcome may require
dmission to a cardiac care unit or telemetry unit,
reatment with potent antiplatelet agents (35–37), or
arly referral for cardiac catheterization (38). MCE
an be used to provide earlier and more accurate triage
f these patients than clinical evaluation with the
hrombolysis In Myocardial Infarction (TIMI) risk
core (39), which is derived from multiple clinical
ariables including cardiac troponin-I (cTNI). Be-
ause cTNI may not be elevated or immediately
vailable at the time of patient presentation, complete risk stratification and initiation of therapy may be
nnecessarily delayed.
The prognostic utility of a score derived only from
ariables that are available immediately at the time of
patient’s presentation to the ED was evaluated (34).
ecause laboratory results may not be received for
any hours after the initial presentation, a modified
IMI risk score (mTIMI) that excluded cTNI was
erived (maximum score of 6). Based on their mTIMI
cores, patients were categorized as either low (score
2), intermediate (score of 3 or 4), or high (score5)
isk. Although patients with a low mTIMI score had
he lowest incidence of primary events, 4.1% of pa-
ients still had an early AMI within 24 h of enroll-
ent. Patients with an intermediate score had a
imilar event rate as those with a high-risk score (11%
ersus 8.9%, p  0.71). Thus, the mTIMI score was
nable to discriminate between these groups (34).
With MCE, on the other hand, the incidence of a
rimary (nonfatal AMI or total mortality) event
ithin 24 h of enrollment was only 0.4% in patients
ith normal WT and MP. In comparison, a 2.3%
MI rate has been reported for patients with CP
ischarged from the ED based on routine evaluation
9). The negative predictive value of MCE is therefore
xcellent. Even in patients with a low mTIMI score,
CE provides further risk stratification. Those pa-
ients with abnormal WT and MP had a significantly
orse cardiac outcome than patients with normal
CE (34). The ability of MCE to provide incremen-
al intermediate (30 day) and late (2 year) prognostic
nformation was also shown in these studies (33,34).
Since MCE data can potentially be obtained im-
ediately at the bedside when a patient with CP
resents to an ED, we hypothesized that a risk score
ncorporating clinical, ECG, and MCE variables
ould accurately predict adverse events occurring
ithin 48 h of presentation. We developed a logistic
isk model in an initial cohort of 1,166 patients, and
ubsequently validated the model in a subsequent
ohort of 720 patients. Significant multivariate pre-
ictors of nonfatal myocardial infarction or cardiac
eath within 48 h of presentation were found to be
onspecific ST-T changes on the ECG, any abnor-
ality on the ECG, abnormal WT, or abnormal MP;
ach predictor was assigned a value of 1, with the risk
core for each patient being the sum total. Patients
ith a risk score of 0 were found to have an early event
ate of 0.3%, which increased significantly to an event
ate of 58% for those with a maximum risk score of 4
n cohort 1. Likewise, in cohort 2, the risk score-
tratified patients into 5 distinct risk groups with event
ates ranging from 0.5% to 50% (40).
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201ost Effectiveness of MCE
he addition of contrast-enhanced echocardiography
o the evaluation of all CP patients could dramatically
ncrease the already high cost associated with these
D visits. It has been shown, though, that MCE can
e cost efficient in such patients by detecting those
hose CP is noncardiac in nature and reducing
nnecessary admissions or other downstream cardiac
esting. A cost-efficiency analysis was performed in
57 patients presenting to the ED with suspected
ardiac CP, but no ST-segment elevation on the
CG, who underwent MCE. On the basis of routine
linical criteria without knowledge of MCE findings,
41 (67%) patients were admitted to the hospital,
hereas 316 (33%) were discharged directly from the
D. The average cost per patient using routine eval-
ation was $5,000. Since patients with normal MCE
ave a very low early primary cardiac event rate of
.6%, such patients could have been discharged di-
ectly from the ED. Hence, if MCE had been used for
ecision making, 55% of patients would have been
ischarged directly from the ED. Preventing unnec-
ssary admissions and tests would have saved an
verage of $900 per patient, in addition to reducing
heir ED stay (41).
afety of MCE in ACS
he black box warning initially imposed by the
ederal Drug Administration in October 2007 was
evised in May 2008 and no longer restricts the use of
chocardiographic contrast agents in patients with
uspected ACS. The safety of echocardiographic con-
rast agents has been documented in many large
etrospective registries. The risk of an anaphylactoid
eaction is 1:15,000, which is much lower than the risk
f an allergic reaction to iodinated radiographic con-
rast agents used for computed tomography coronary
ngiography or cardiac catheterization, which would
e alternatives to MCE in the ACS population
42). Another retrospective analysis of 58,000
oses of ultrasound contrast agents administered to
4.2 million hospitalized patients showed no dif-
erence in 24-h mortality between those who re-
eived contrast versus those who did not, despite
hose receiving contrast agents having a signifi-
antly higher frequency of unstable cardiopulmo-
ary conditions (43). The safety of Sonovue (Bracco
maging SpA, Milan, Italy), which is currently
vailable in Europe, has been prospectively evalu-
ted in 500 patients undergoing stress MCE 2 to 5
ays after presenting with CP to the ED. The
uthors reported no deaths, AMI, significant ar- Ohythmias, or any other life-threatening events.
dverse events were not significantly different be-
ween the MCE group and the control group (44).
he Federal Drug Administration has recom-
ended 30 min of monitoring in patients with
nown or suspected ACS who receive ultrasound
ontrast agents, which should be easily accommo-
ated in the ED.
mplementation of MCE in the ED
lthough performance of MCE may be feasible
uring the day in most medical centers, the logistics of
ighttime performance and interpretation of images
ill have to be individualized for each site. At our
enter, cardiology fellows are trained in the perfor-
ance of contrast-enhanced studies for left ventricular
pacification, and we also have sonographers on call.
ites could consider adding evening shifts for sonog-
aphers to increase the hours of coverage or use other
reative solutions. As ultrasound technology becomes
ore incorporated into the management of acutely ill
atients in future, appropriately trained ED physicians
ay themselves perform focused cardiac ultrasound
tudies on patients with suspected ACS, similar to the
ncorporation of ultrasound in the Focused Assess-
ent with Sonography in Trauma (FAST) exam.
The evaluation of WT abnormalities on echocar-
iography is one of the most subjective and difficult
kills to master. Interpreters should therefore be expe-
ienced, well-trained echocardiographers. Most image
eview software now offers secure on-line access of
igitally acquired MCE images to allow rapid inter-
retation of WT and/or MP at night or on weekends.
ummary
CE meets most of the requirements of an ideal tool
or the assessment of suspected cardiac CP: it can
irectly assess the degree and adequacy of MP as well
s the presence of WT abnormalities. It is rapid,
oninvasive, highly accurate, safe, and portable. The
ssessment of WT and MP provides incremental
iagnostic and prognostic information over other clin-
cal variables that are routinely used today. Further-
ore, by accurately excluding cardiac CP and prevent-
ng unnecessary hospitalizations or cardiac testing,
CE can even reduce the cost of managing these
hallenging patients.
eprint requests and correspondence: Dr. Kevin Wei,
181 SW Sam Jackson Park Road, UHN 62, Portland,
regon 97239. E-mail: weik@ohsu.edu.
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